Eli Lilly to acquire Dermira for $1.1 billion
16-01-2020
Fed Circ affirms Eli Lilly victories over cancer drugs
13-08-2019
Jonathan Weiss / Shutterstock.com
Eli Lilly is expanding its genetics business with the $880 million purchase of Prevail Therapeutics, in a deal that could rise to more than $1 billion.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Eli, Lilly, Prevail, Therapeutics, genetics, Gaucher, disease, Mark, Mintun, Parkinson, neurodegenerative, dementia, pipeline
